AI Article Synopsis
- Drug-Induced Pulmonary Arterial Hypertension (PAH) is commonly associated with appetite-suppressing drugs, but Interferon-β (IFN-β) is also a potential risk factor.
- A case study highlights a patient with Multiple Sclerosis who developed PAH while being treated with IFN-β, detailing her treatment and disease progression.
- The article includes a review of existing research on the relationship between IFN-β and the development of PAH.
Article Abstract
Drug-Induced Pulmonary Arterial Hypertension (PAH) represents a well-known entity, predominantly related to anorexigens. Interferon-β (IFN) is considered to be a drug with a possible risk of inducing PAH. We report a patient with Multiple Sclerosis treated with IFN-β who diagnosed with PAH and her course of disease under specific PAH drug therapy. A review of the literature in IFN-β-induced PAH is provided.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2019.01.018 | DOI Listing |
Publication Analysis
Top Keywords
pulmonary arterial
8
arterial hypertension
8
multiple sclerosis
8
pah
5
hypertension associated
4
associated interferon-beta
4
interferon-beta treatment
4
treatment multiple
4
sclerosis case
4
case report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!